Source comparison
Tesamorelin Cycle: Protocol Comparison
Conservative Fat Loss 1mg Morning fasted 12 weeks 80–120% above baseline 4 weeks Ideal for initial cycles. Lower dose reduces injection site reactions while maintaining 70% of maximal efficacy Standard Research Protocol 2mg 16–20 weeks 150–200% above baseline
This comparison does not assign a generated winner or score.
- Conservative Fat Loss
- 1mg
- Morning fasted
- 12 weeks
- 80–120% above baseline
- 4 weeks
- Ideal for initial cycles. Lower dose reduces injection site reactions while maintaining 70% of maximal efficacy
- Standard Research Protocol
- 2mg
- 16–20 weeks
- 150–200% above baseline
- 6–8 weeks
- Most-studied protocol. Aligns with clinical trial design and produces consistent results across diverse research models
- Extended Cycle
- 26 weeks
- Peaks at week 16–20, plateaus thereafter
- 8 weeks
- Marginal benefit beyond week 20. Extended duration increases desensitisation risk without proportional IGF-1 gain
- Split-Dose Protocol
- 1mg twice daily
- Morning + evening fasted
- 12–16 weeks
- 140–180% above baseline
- 6 weeks
- Mimics natural pulsatile pattern but requires strict meal timing. No clear superiority over single morning dose